Results 231 to 240 of about 2,642,573 (281)

De Novo Discovery of Nonstandard Thioisoindole‐Bridged Bicyclic Peptides Targeting Traf2‐ and NCK‐Interacting Kinase

open access: yesAngewandte Chemie, Volume 138, Issue 41, 5 October 2026.
An optimized strategy for the ribosomal synthesis of thioisoindole‐bridged bicyclic (TiB) peptides is incorporated into the RaPID platform, enabling high‐throughput discovery from topologically defined TiB libraries. Proof‐of‐concept selection against TNIK identifies nanomolar‐affinity ligands with inhibitory activity, while x‐ray crystallography ...
Yue Zhang   +5 more
wiley   +2 more sources

Innovative Field Applications of Probiotics, Prebiotics, and Medicinal Plant Products for Disease Control in Aquaculture

open access: yesJournal of Fish Diseases, Volume 49, Issue 11, November 2026.
ABSTRACT Disease outbreaks and the associated reliance on antibiotics pose major constraints to the sustainability of modern aquaculture. As regulatory pressures increase and consumer demand shifts toward residue‐free production, diverse biological interventions are gaining prominence as viable alternatives to chemotherapeutics.
Mustafa Öz   +5 more
wiley   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

open access: yesChemistry – A European Journal, Volume 32, Issue 39, 22 October 2026.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA. [PDF]

open access: yesLancet Infect Dis
Ulloa ER   +9 more
europepmc   +1 more source

Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge. [PDF]

open access: yesPharmaceuticals (Basel)
Gallina A   +5 more
europepmc   +1 more source

Phage Therapy

open access: yesNature Reviews Methods Primers
Bacteriophage (phages) are viruses that exclusively use bacterial cells for propagation, killing the bacterial host in the process. In phage therapy, phages are used to reduce bacterial numbers, thereby curing bacterial infections. Although this principle is conceptually straightforward, its practical application faces several hurdles.
Thomas Sicheritz-Ponten   +2 more
exaly   +11 more sources
Some of the next articles are maybe not open access.

Related searches:

Phage therapy

Drug Discovery Today, 2009
There is a renaissance of interest in the antimicrobial potential of phages as more pathogens become multiply antibiotic resistant. Phage therapy is not a new concept, and it is important to ask why it is not part of the current repertoire of western medicine despite the fact that it has been continuously and extensively used in Eastern Europe for ...
John N, Housby, Nicholas H, Mann
openaire   +2 more sources

Phage for cancer therapy

2023
Cancer is currently a global health challenge, characterized by dysfunction of organs due to the uncontrolled growth of cells exponentially. The therapies used to treat cancer in patients so far are widely used. However, there are also some problems, such as the high cost of surgery and chemotherapy.
Hue Vu, Thi   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy